Related Experiment Videos

Response to: 'Serum complement factor C5a in IgG4-related disease' by Fukui et al

Hisanori Umehara¹, Mitsuhiro Kawano²

¹Division of RA and Autoimmune Diseases, Nagahama City Hospital, Shiga, Japan.

Annals of the Rheumatic Diseases

|June 8, 2018

Abstract

No abstract available in PubMed .

Keywords:

disease activity inflammation treatment

Related Concept Videos

Articles linked to this work by shared authors, journal, and citation graph.

Durable platelet response and immature platelet indices following sequential efgartigimod and eltrombopag therapy in a patient with refractory ITP.

Platelets·2026

DAS28-ESR may underestimate disease activity in rheumatoid arthritis patients with nonalcoholic fatty liver disease: a retrospective cohort study.

Arthritis research & therapy·2026

Clinical characteristics of acute pancreatitis in patients with inflammatory bowel disease: a nationwide survey in Japan.

Journal of gastroenterology·2026

Effectiveness and Safety of Inebilizumab for IgG4-Related Disease in a Real-World Clinical Setting in Japan: Protocol for a Long-Term Prospective Observational Study (4SigHT Study).

Rheumatology and therapy·2026

Obexelimab for the Treatment of IgG4-Related Disease.

The New England journal of medicine·2026

Inebilizumab treatment in Japanese patients with IgG4-related disease: a subgroup analysis of a randomized, double-blind, placebo-controlled, phase 3 trial (MITIGATE).

Modern rheumatology·2026

See all related articles